Literature DB >> 21724679

Modern management of malignant hypercalcemia.

Susan B Legrand1.   

Abstract

Hypercalcemia occurs in 10% to 20% of those with advanced cancer. It is considered an oncologic emergency. Presenting symptoms include common gastrointestinal symptoms that may be difficult to differentiate from tumor or treatment-related symptoms. These include nausea, vomiting, and constipation. As levels increase or if development is rapid, neuropsychiatric symptoms such as delirium can develop. Untreated it will lead to coma and death. Current preferred therapies are the bisphosphonate agents, zoledronate and pamidronate with saline rehydration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724679     DOI: 10.1177/1049909111414164

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  4 in total

1.  Physicians' attitude toward recurrent hypercalcemia in terminally ill cancer patients.

Authors:  Akira Shimada; Ichiro Mori; Isseki Maeda; Hidekazu Watanabe; Nobutaka Kikuchi; Hansheng Ding; Tatsuya Morita
Journal:  Support Care Cancer       Date:  2014-07-22       Impact factor: 3.603

2.  Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.

Authors:  Shreyashee Mallik; Girijasankar Mallik; Shireen Teves Macabulos; Andrew Dorigo
Journal:  Support Care Cancer       Date:  2015-10-06       Impact factor: 3.603

Review 3.  Diagnosis and Management of Oncologic Emergencies.

Authors:  Sarah Klemencic; Jack Perkins
Journal:  West J Emerg Med       Date:  2019-02-14

4.  Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.

Authors:  Ricardo Emanuel de Oliveira Ramos; Milena Perez Mak; Michel Fabiano Silva Alves; Gustavo Henrique Munhoz Piotto; Tiago Kenji Takahashi; Leonardo Gomes da Fonseca; Marina Cavalcanti Maroja Silvino; Paulo Marcelo Hoff; Gilberto de Castro
Journal:  J Glob Oncol       Date:  2017-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.